Current concepts in colorectal cancer prevention

References

• Stewart SL, Wike JM, Kato I, Lewis DR, Michaud F. A population-based study of colorectal cancer histology in the United States, 1998–2001. Cancer107(Suppl. 5), 1128–1141 (2006).
   PubMed Web of Science ®Google Scholar
• Jass JP. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology50(1), 113–130 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson-Thompson J, Ahmed F, German RR, Lai S-M, Friedman C. Descriptive epidemiology of colorectal cancer in the United States, 1998–2001. Cancer107(Suppl. 5), 1103–1111 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobs ET, Thompson PA, Martinez ME. Diet, gender, and colorectal neoplasia. J. Clin. Gastroenterol.41(8), 731–746 (2007).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease. Cancer91(4), 854–862 (2001).
   PubMed Web of Science ®Google Scholar
• Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod. Pathol.16(4), 347–358 (2003).
   PubMed Web of Science ®Google Scholar
• Winawer SJ, Zauber AG, Fletcher RH et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US multi-society task force on colorectal cancer and the american cancer society. Gastroenterology130(6), 1872–1885 (2006).
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Weiss DG, Harford WV et al. Five-year colon surveillance after screening colonoscopy. Gastroenterology133(4), 1077–1085 (2007).
   PubMed Web of Science ®Google Scholar
• Martínez ME, Baron JA, Lieberman DA et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology136(3), 832–841 (2009).
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N. Engl. J. Med.359(12), 1218–1224 (2008).
   PubMed Web of Science ®Google Scholar
• Strul H, Kariv R, Leshno M et al. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40–80 years. Am. J. Gastroenterol.101(2), 255–262 (2006).
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans affairs cooperative study group 380. N. Engl. J. Med.343(3), 162–168 (2000).
   PubMed Web of Science ®Google Scholar
• Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N. Engl. J. Med.326(10), 658–662 (1992).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Sonnenberg A, Amorosi SL, Lacey MJ, Lieberman DA. Patterns of endoscopy in the United States: analysis of data from the centers for medicare and medicaid services and the national endoscopic database. Gastrointest. Endosc.67(3), 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. N. Engl. J. Med.329(27), 1977–1981 (1993).
   PubMed Web of Science ®Google Scholar
• McLaren CE, Fujikawa-Brooks S, Chen WP et al. Longitudinal assessment of air conduction audiograms in a Phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev. Res. (Phila. PA)1(7), 514–521 (2008).
   PubMed Web of Science ®Google Scholar
• Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer and the American College of Radiology. Gastroenterology134(5), 1570–1595 (2008).
   PubMed Web of Science ®Google Scholar
• McFarland EG, Levin B, Lieberman DA et al. Revised colorectal screening guidelines: joint effort of the American Cancer Society, US Multisociety Task Force on Colorectal Cancer and American College Of Radiology. Radiology248(3), 717–720 (2008).
   PubMed Web of Science ®Google Scholar
• Mitka M. Colorectal cancer screening rates still fall far short of recommended levels. JAMA299(6), 622 (2008).
   PubMed Web of Science ®Google Scholar
• Ko CW, Riffle S, Shapiro JA et al. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest. Endosc.65(4), 648–656 (2007).
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta GD, Mosconi S, Milesi L, Pessi MA. Colorectal cancer: screening. Ann. Oncol.16(Suppl. 2), ii127–ii132 (2005).
   PubMedGoogle Scholar
• Laiyemo AO, Murphy G, Albert PS et al. Postpolypectomy colonoscopy surveillance guidelines: predictive accuracy for advanced adenoma at 4 years. Ann. Intern. Med.148(6), 419–426 (2008).
   PubMed Web of Science ®Google Scholar
• Robertson DJ, Greenberg ER, Beach M et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology129(1), 34–41 (2005).
   PubMed Web of Science ®Google Scholar
• Jørgensen OD, Kronborg O, Fenger C, Rasmussen M. Influence of long-term colonoscopic surveillance on incidence of colorectal cancer and death from the disease in patients with precursors (adenomas). Acta. Oncol. (Madr.)46(3), 355–360 (2007).
   PubMed Web of Science ®Google Scholar
• Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med.150(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Park D, Kim H, Kim W et al. clinicopathologic characteristics and malignant potential of colorectal flat neoplasia compared with that of polypoid neoplasia. Dis. Colon Rectum51(1), 43–49 (2008).
   PubMed Web of Science ®Google Scholar
• Heresbach D, Barrioz T, Lapalus MG et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy40(4), 284–290 (2008).
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Fujii T, Cairns A et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet355(9211), 1211–1214 (2000).
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Waxman I, West AB et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology120(7), 1657–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Speake D, Biyani D, Frizelle FA, Watson AJM. Flat adenomas. ANZ J. Surg.77(1–2), 4–8 (2007).
   PubMed Web of Science ®Google Scholar
• Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology132(1), 96–102 (2007).
   PubMed Web of Science ®Google Scholar
• Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N. Engl. J. Med.355(24), 2533–2541 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson CD, Chen M-H, Toledano AY et al. Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med.359(12), 1207–1217 (2008).
   PubMed Web of Science ®Google Scholar
• Dominitz JA, Robertson DJ. Colorectal cancer screening with computed tomographic colonography. Gastroenterology136(4), 1451–1453 (2009).
   PubMedGoogle Scholar
• Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc.35(6), 1332–1338 (1976).
   PubMedGoogle Scholar
• Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenterol. Clin. North Am.25(4), 717–735 (1996).
   PubMed Web of Science ®Google Scholar
• Baron JA. Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res.181, 223–229 (2009).
   PubMedGoogle Scholar
• Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl Cancer Inst.101(4), 256–266 (2009).
   PubMed Web of Science ®Google Scholar
• Newcomb PA, Pocobelli G, Chia V. Why hormones protect against large bowel cancer: old ideas, new evidence. Adv. Exp. Med. Biol.617, 259–269 (2008).
   PubMed Web of Science ®Google Scholar
• Martinez ME, Marshall JR, Giovannucci E. Diet and cancer prevention: the roles of observation and experimentation. Nat. Rev. Cancer8(9), 694–703 (2008).
   PubMed Web of Science ®Google Scholar
• Vander Meer R, Lapre JA, Govers MJ, Kleibeuker JH. Mechanisms of the intestinal effects of dietary fats and milk products on colon carcinogenesis. Cancer Lett.114(1–2), 75–83 (1997).
   PubMed Web of Science ®Google Scholar
• Baron JA, Beach M, Mandel JS et al. calcium supplements for the prevention of colorectal adenomas. N. Engl. J. Med.340(2), 101–107 (1999).
   PubMed Web of Science ®Google Scholar
• Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet356(9238), 1300–1306 (2000).
   PubMed Web of Science ®Google Scholar
• Hofstad B, Almendingen K, Vatn M et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion59(2), 148–156 (1998).
   PubMed Web of Science ®Google Scholar
• Wactawski-Wende J, Kotchen JM, Anderson GL et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N. Engl. J. Med.354(7), 684–696 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res.589(1), 47–65 (2005).
   PubMed Web of Science ®Google Scholar
• Hill MJ, Aries VC. Faecal steroid composition and its relationship to cancer of the large bowel. J. Pathol.104(2), 129–139 (1971).
   PubMed Web of Science ®Google Scholar
• Jensen OM, MacLennan R, Wahrendorf J. Diet, bowel function, fecal characteristics, and large bowel cancer in Denmark and Finland. Nutr. Cancer4(1), 5–19 (1982).
   PubMedGoogle Scholar
• McKeigue PM, Adelstein AM, Marmot MG et al. Diet and fecal steroid profile in a South Asian population with a low colon-cancer rate. Am. J. Clin. Nutr.50(1), 151–154 (1989).
   PubMed Web of Science ®Google Scholar
• Reddy BS, Hedges A, Laakso K, Wynder EL. Fecal constituents of a high-risk North American and a low-risk Finnish population for the development of large bowel cancer. Cancer Lett.4(4), 217–222 (1978).
   PubMed Web of Science ®Google Scholar
• Hill MJ, Drasar BS, Williams RE et al. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet1(7906), 535–539 (1975).
   PubMed Web of Science ®Google Scholar
• Imray CH, Radley S, Davis A et al. Faecal unconjugated bile acids in patients with colorectal cancer or polyps. Gut33(9), 1239–1245 (1992).
   PubMed Web of Science ®Google Scholar
• Nordling MM, Glinghammar B, Karlsson PC, de Kok TM, Rafter JJ. Effects on cell proliferation, activator protein-1 and genotoxicity by fecal water from patients with colorectal adenomas. Scand. J. Gastroenterol.38(5), 549–555 (2003).
   PubMed Web of Science ®Google Scholar
• Tong JL, Ran ZH, Shen J, Fan GQ, Xiao SD. Association between fecal bile acids and colorectal cancer: a meta-analysis of observational studies. Scand. J. Gastroenterol.49(5), 792–803 (2008).
   Google Scholar
• Reddy BS, Narasawa T, Weisburger JH, Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J. Natl Cancer Inst.56(2), 441–442 (1976).
   PubMed Web of Science ®Google Scholar
• Gustav Paumgartner UB. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology36(3), 525–531 (2002).
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med.134(2), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology124(4), 889–893 (2003).
   PubMed Web of Science ®Google Scholar
• Earnest DL, Holubec H, Wali RK et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res.54(19), 5071–5074 (1994).
   PubMed Web of Science ®Google Scholar
• Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis22(1), 35–41 (2001).
   PubMed Web of Science ®Google Scholar
• Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J. Nutr.134(2), 483–486 (2004).
   PubMed Web of Science ®Google Scholar
• Wali RK, Khare S, Tretiakova M et al. Ursodeoxycholic acid and F6-D3 inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol. Biomarkers Prev.11(12), 1653–1662 (2002).
   PubMed Web of Science ®Google Scholar
• Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett.134(2), 129–139 (1998).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Martinez ME, Hess LM et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J. Natl Cancer Inst.97(11), 846–853 (2005).
   PubMed Web of Science ®Google Scholar
• Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis. Colon Rectum44(1), 77–85 (2001).
   PubMed Web of Science ®Google Scholar
• Marchesa P, Lashner BA, Lavery IC et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am. J. Gastroenterol.92(8), 1285–1288 (1997).
   PubMed Web of Science ®Google Scholar
• Thomas LA, Veysey MJ, French G, Hylemon PB, Murphy GM, Dowling RH. Bile acid metabolism by fresh human colonic contents: a comparison of caecal versus faecal samples. Gut49(6), 835–842 (2001).
   PubMed Web of Science ®Google Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst.94(4), 252–266 (2002).
   PubMed Web of Science ®Google Scholar
• Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer6(2), 130–140 (2006).
   PubMed Web of Science ®Google Scholar
• Hawk ET, Levin B. Colorectal cancer prevention. J. Clin Oncol.23(2), 378–391 (2005).
   PubMed Web of Science ®Google Scholar
• Vasen HFA, Moslein G, Alonso A et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut57(5), 704–713 (2008).
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol.231(25), 232–235 (1971).
   PubMedGoogle Scholar
• Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol.23(12), 2840–2855 (2005).
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med.356(21), 2131–2142 (2007).
   PubMed Web of Science ®Google Scholar
• Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl Cancer Inst.85(15), 1220–1224 (1993).
   PubMed Web of Science ®Google Scholar
• Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. aspirin use and colorectal cancer: post-trial follow-up data from the physicians’ health study. Ann. Intern. Med.128(9), 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the women’s health study: a randomized controlled trial. JAMA294(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet369(9573), 1603–1613 (2007).
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med.348(10), 891–899 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez ME, O’Brien TG, Fultz KE et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc. Natl Acad. Sci. USA100(13), 7859–7864 (2003).
   PubMed Web of Science ®Google Scholar
• Barry EL, Baron JA, Bhat S et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J. Natl Cancer Inst.98(20), 1494–1500 (2006).
   PubMedGoogle Scholar
• Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin. Cancer Res.14(8), 2303–2309 (2008).
   PubMed Web of Science ®Google Scholar
• Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res.56(20), 4566–4569 (1996).
   PubMed Web of Science ®Google Scholar
• Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology134(4), 1224–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol. Biomarkers Prev.17(8), 1852–1857 (2008).
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology133(2), 393–402 (2007).
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr. Pharm. Des.13(22), 2215–2227 (2007).
   PubMed Web of Science ®Google Scholar
• Groden J, Thliveris A, Samowitz W et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell66(3), 589–600 (1991).
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of b-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis21(11), 1935–1940. (2000).
   PubMed Web of Science ®Google Scholar
• Fultz KE, Gerner EW. APC-dependent regulation of ornithine decarboxylase in human colon tumor cells. Mol. Carcinog.34(1), 10–18 (2002).
   PubMed Web of Science ®Google Scholar
• Roy UK, Henkhaus RS, Ignatenko NA, Mora J, Fultz KE, Gerner EW. Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc. Mol. Carcinog.47(12), 947–955 (2008).
   PubMed Web of Science ®Google Scholar
• Roy UK, Rial NS, Kachel KL, Gerner EW. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol. Carcinog.47(7), 538–553 (2008).
   PubMed Web of Science ®Google Scholar
• Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation19(1), 1–20 (1981).
   PubMed Web of Science ®Google Scholar
• Janne J, Alhonen L, Leinonen P. Polyamines: from molecular biology to clinical applications. Ann. Med.23(3), 241–259 (1991).
   PubMed Web of Science ®Google Scholar
• Tabor CW, Tabor H. Polyamines. Annu. Rev. Biochem.53, 749–790 (1984).
   PubMed Web of Science ®Google Scholar
• Igarashi K, Kashiwagi K. Polyamines: mysterious modulators of cellular functions. Biochem. Biophys. Res. Commun.271(3), 559–564 (2000).
   PubMed Web of Science ®Google Scholar
• Matsufuji S, Matsufuji T, Miyazaki Y et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell80(1), 51–60 (1995).
   PubMed Web of Science ®Google Scholar
• Lux GD, Marton LJ, Baylin SB. Ornithine decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats. Science210(4466), 195–198 (1980).
   PubMed Web of Science ®Google Scholar
• McCormack SA, Johnson LR. Polyamines and cell migration. J. Physiol. Pharmacol.52(3), 327–349 (2001).
   PubMed Web of Science ®Google Scholar
• Hixson LJ, Garewal HS, McGee DL et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol. Biomarkers Prev.2(4), 369–374 (1993).
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res.57(2), 199–201 (1997).
   PubMed Web of Science ®Google Scholar
• Erdman SH, Ignatenko NA, Powell MB et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis in the Min mouse. Carcinogenesis20(9), 1709–1713 (1999).
   PubMed Web of Science ®Google Scholar
• Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J. Natl Cancer Inst.77(6), 1309–1313 (1986).
   PubMedGoogle Scholar
• Pereira MA, Khoury MD. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett.61(1), 27–33 (1991).
   PubMed Web of Science ®Google Scholar
• Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J. Biochem.139, 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ. X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with α-difluoromethylornithine. Biochemistry38(46), 15174–15184 (1999).
   PubMed Web of Science ®Google Scholar
• Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by α-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. Chem.267(1), 150–158 (1992).
   PubMed Web of Science ®Google Scholar
• Hixson LJ, Emerson SS, Shassetz LR, Gerner EW. Sources of variability in estimating ornithine decarboxylase activity and polyamine contents in human colorectal mucosa. Cancer Epidemiol. Biomarkers Prev.3(4), 317–323 (1994).
   PubMed Web of Science ®Google Scholar
• Meyskens FL Jr, Gerner EW, Emerson S et al. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J. Natl Cancer Inst.90(16), 1212–1218 (1998).
   PubMed Web of Science ®Google Scholar
• Meyskens FL Jr, Emerson SS, Pelot D et al. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J. Natl Cancer Inst.86(15), 1122–1130 (1994).
   PubMedGoogle Scholar
• Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr. Opin. Investig. Drugs2(5), 677–683 (2001).
   PubMedGoogle Scholar
• Piazza GA, Alberts DS, Hixson LJ et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res.57(14), 2909–2915 (1997).
   PubMed Web of Science ®Google Scholar
• Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr. Cancer43(1), 1–21 (2002).
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Offerhaus JA, Tersmette AC et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut38(4), 578–581 (1996).
   PubMed Web of Science ®Google Scholar
• Babbar N, Gerner EW, Casero RA Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in caco-2 colon cancer cells. Biochem. J.394(Pt 1), 317–324 (2006).
   PubMed Web of Science ®Google Scholar
• Babbar N, Ignatenko NA, Casero RA Jr, Gerner EW. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J. Biol. Chem.278(48), 47762–47775 (2003).
   PubMed Web of Science ®Google Scholar
• Gerner EW, Meyskens FL Jr .Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer4(10), 781–792 (2004).
   PubMed Web of Science ®Google Scholar
• Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr. Cancer60(Suppl. 1), 30–35 (2008).
   PubMed Web of Science ®Google Scholar
• Uemura T, Yerushalmi HF, Tsaprailis G et al. Identification and characterization of a diamine exporter in colon epithelial cells. J. Biol. Chem.283(39), 26428–26435 (2008).
   PubMed Web of Science ®Google Scholar
• Yerushalmi HF, Besselsen DG, Ignatenko NA et al. The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis. Mol. Carcinog.45(2), 93–105 (2006).
   PubMed Web of Science ®Google Scholar
• Yerushalmi HF, Besselsen DG, Ignatenko NA et al. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol. Carcinog.45(10), 764–773 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein H, Holubec H, Bernstein C et al. Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles. Dig. Dis. Sci.52(3), 628–642 (2007).
   PubMed Web of Science ®Google Scholar
• Boyle JO, Meyskens FL Jr, Garewal HS, Gerner EW. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol. Biomarkers Prev.1(2), 131–135 (1992).
   PubMed Web of Science ®Google Scholar
• Einspahr JG, Alberts DS, Gapstur SM, Bostick RM, Emerson SS, Gerner EW. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev.6(1), 37–48 (1997).
   PubMed Web of Science ®Google Scholar
• Finley PR, Bogert CL, Alberts DS et al. Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol. Biomarkers Prev.4(3), 239–244 (1995).
   PubMed Web of Science ®Google Scholar
• Calaluce R, Earnest DL, Heddens D et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized Phase IIb trial. Cancer Epidemiol. Biomarkers Prev.9(12), 1287–1292 (2000).
   PubMed Web of Science ®Google Scholar
• Meyskens FLJ, McLaren, CE, Pelot D. et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo controlled, double-blind trial. Cancer Prev. Res. (Phila. PA)1, 32–38 (2008).
   PubMed Web of Science ®Google Scholar
• Sporn MB, Hong WK. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prev. Res. (Phil.)1(1), 9–11 (2008).
   PubMed Web of Science ®Google Scholar
• Sporn MB. Combination chemoprevention of cancer. Nature287(5778), 107–108 (1980).
   PubMed Web of Science ®Google Scholar
• Kahi CJ, Rex DK. Primer: Applying the new postpolypectomy surveillance guidelines in clinical practice. Nat. Clin. Pract. Gastroenterol. Hepatol.4(10), 571–578 (2007).
   PubMedGoogle Scholar
• Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med.355(9), 885–895 (2006).
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med.355(9), 873–884 (2006).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N. Engl. J. Med.355(9), 950–952 (2006).
   PubMed Web of Science ®Google Scholar
• Zell JA, Pelo D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Baseline cardiovascular risk in cancer chemoprevention clinical trials involving NSAIDs: a re-analysis of cardiovascular toxicity from a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev. Res. (Phila. PA) (2009) (In Press).
   PubMedGoogle Scholar
• Solomon SD, Wittes J, Finn PV et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation117(16), 2104–2113 (2008).
   PubMed Web of Science ®Google Scholar
• Chan AT, Zauber AG, Hsu M et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology136(7), 2127–2136 (2009).
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Baron JA, Tosteson TD et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N. Engl. J. Med.331(3), 141–147 (1994).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Martinez ME, Roe DJ et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix colon cancer prevention physicians’ network. N. Engl. J. Med.342(16), 1156–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Cole BF, Baron JA, Sandler RS et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA297(21), 2351–2359 (2007).
   PubMed Web of Science ®Google Scholar
• Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology134(1), 29–38 (2008).
   PubMed Web of Science ®Google Scholar